In this context, saroglitazar, a dual PPAR α/γ agonist, has emerged as a promising drug that is approved for managing indications like diabetic dyslipidemia (DD), MASLD, and type 2 diabetes mellitus (T2DM). The gene discussed is PPARA; the disease is type 2 diabetes mellitus.